On October 8, 2026, Beyond Air, Inc. (NASDAQ: XAIR) announced preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026. The company stated that this figure represents the highest quarterly revenue reported to date. The revenue reflects a sequential increase of approximately 30% compared to the prior quarter and a 27% increase over the same period in the previous year. The growth is attributed to continued adoption of the company's first-generation LungFit PH system.
Beyond Air noted that its second-generation LungFit PH system remains under review by the U.S. Food and Drug Administration (FDA). The company reaffirmed its previously issued revenue guidance for calendar year 2026 and 2027. For 2026, the guidance excludes revenue from the second-generation system and is set at $8 million. For 2027, the guidance of $16 million to $18 million includes anticipated revenue from the second-generation system, pending FDA approval.
The company emphasized that the preliminary revenue figure is unaudited and based on management's estimates. It remains subject to the completion of financial closing procedures and review by the independent registered public accounting firm. Actual results may differ materially from these preliminary figures. Beyond Air expects to report its complete financial results for the quarter ended September 30, 2026, in November 2026.
